Use of α2-agonists in neuroanesthesia: An overview

Ochsner Journal

Volumn 11, Issue 1, 2011, Pages 57-69

  Farag, Ehab ^a   Argalious, Maged ^a   Sessler, Daniel I ^a   Kurz, Andrea ^a   Ebrahim, Zeyd Y ^a   Schubert, Armin ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Alpha 2 agonist; Anesthesia; Dexmedetomidine; Neuroanesthesia; Neuroprotection

Indexed keywords

ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANESTHETIC AGENT; BRIMONIDINE; CALCIUM ION; CATECHOLAMINE; CLONIDINE; DEXMEDETOMIDINE; EXCITATORY AMINO ACID TRANSPORTER; GLUTAMIC ACID; HALOTHANE; ISOFLURANE; LACTATE DEHYDROGENASE; LORAZEPAM; MIDAZOLAM; OPIATE; PHENYLEPHRINE; PLACEBO; PROPOFOL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; REMIFENTANIL; XENON;

ADJUVANT THERAPY; ANESTHESIA INDUCTION; AREA UNDER THE CURVE; ARTICLE; BRADYCARDIA; BRAIN BLOOD FLOW; BRAIN DEPTH STIMULATION; BRAIN DEVELOPMENT; BRAIN ISCHEMIA; BRAIN METABOLISM; CARDIOVASCULAR DISEASE; CATECHOLAMINE RELEASE; CLINICAL STUDY; COMPLEX REGIONAL PAIN SYNDROME; CONTRAST INDUCED NEPHROPATHY; CRANIOTOMY; DELIRIUM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DYSTONIA; EVOKED MUSCLE RESPONSE; EXCITOTOXICITY; GENERAL ANESTHESIA; HUMAN; HYPERACTIVITY; HYPERCAPNIA; HYPERTENSION; HYPOTENSION; INTENSIVE CARE; INTENSIVE CARE UNIT; LOADING DRUG DOSE; LOW DRUG DOSE; MINIMUM LUNG ALVEOLUS CONCENTRATION; NERVE CELL NECROSIS; NERVOUS SYSTEM INJURY; NEUROMONITORING; NEUROPROTECTION; NEURORADIOLOGY; NONHUMAN; PNEUMONIA; POSTANESTHESIA CARE; RESPIRATION DEPRESSION; SEPSIS; SINGLE DRUG DOSE; TACHYCARDIA; TRAUMATIC BRAIN INJURY;

EID: 79953270377     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Maze M, Tranquilli W. Alpha-2 adrenoceptor agonists: defining the role in clinical anesthesia. Anesthesiology. 1991; 74(3): 581-605.
2. Maze M, Scarfini C, Cavaliere F. New agents for sedation in the intensive care unit. Crit Care Clin. 2001; 17(4): 881-897.
3. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology. 2000; 93(5): 1345-1349.
4. Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists: their pharmacology and therapeutic role. Anaesthesia. 1999; 54(2): 146-165.
5. Wheeler LA, Gil DW, WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001; 45(suppl 3): S291-S294.
6. Danylkova NO, Alcala SR, Pomeranz HD, McLoon LK. Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. Exp Eye Res. 2007; 84(2): 293-301.
7. Merin S, Obolensky A, Farber MD, Chowers I. A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther. 2008; 24(1): 80-86.
8. Engelhard K, Werner C, Kaspar S, et al. Effect of the alpha2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology. 2002; 96(2): 450-457.
9. Ma D, Rajakumaraswamy N, Maze M. alpha2-Adrenoceptor agonists: shedding light on neuroprotection? Br Med Bull. 2005; 71: 77-92.
10. Madison DV, Nicoll RA. Actions of noradrenaline recorded intracellularly in rat hippocampal CA1 pyramidal neurones, in vitro. J Physiol. 1986; 372: 221-244.
11. Stein SC, Cracco RQ. Cortical injury without ischemia produced by topical monoamines. Stroke. 1982; 13(1): 74-83.
12. Hertz L, Dringen R, Schousboe A, Robinson SR. Astrocytes: glutamate producers for neurons. J Neurosci Res. 1999; 57(4): 417-428.
13. Pascual JM, Carceller F, Roda JM, Cerdán S. Glutamate, glutamine, and GABA as substrates for the neuronal and glial compartments after focal cerebral ischemia in rats. Stroke. 1998; 29(5): 1048-1056.
14. Huang R, Chen Y, Yu AC, Hertz L. Dexmedetomidine-induced stimulation of glutamine oxidation in astrocytes: a possible mechanism for its neuroprotective activity. J Cereb Blood Flow Metab. 2000; 20(6): 895-898.
15. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001; 296(1): 216-223.
16. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature. 2000; 403(6767): 316-321.
17. Wheeler LA, Tatton NA, Elstner M, et al. Alpha-2 adrenergic receptor activation by brimonidine reduces neuronal apoptosis through AKT (protein kinase B) dependent new synthesis of BCL-2. Invest Ophthalmol Vis Sci. 2001; 42: S411.
18. Engelhard K, Werner C, Eberspacher E, et al. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosisregulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003; 96(2): 524-531.
19. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003; 48(suppl 1): S47-S51.
20. Laudenbach V, Mantz J, Lagercrantz H, Desmonts JM, Evrard P, Gressens P. Effects of alpha(2)-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of clonidine and dexmedetomidine. Anesthesiology. 2002; 96(1): 134-141.
21. Ma D, Hossain M, Rajakumaraswamy N, et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004; 502(1-2): 87-97.
22. Sanders RD, Xu J, Shu Y, et al. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology. 2009; 110(5): 1077-1085.
23. Karlsson BR, Forsman M, Roald OK, Heier MS, Steen PA. Effect of dexmedetomidine, a selective and potent alpha 2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs. Anesth Analg. 1990; 71(2): 125-129.
24. Asano Y, Koehler RC, Kawaguchi T, McPherson RW. Pial arteriolar constriction to alpha 2-adrenergic agonist dexmedetomidine in the rat. Am J Physiol. 1997; 272(6, pt 2): H2547-H2556.
25. McPherson RW, Koehler RC, Kirsch JR, Traystman RJ. Intraventricular dexmedetomidine decreases cerebral blood flow during normoxia and hypoxia in dogs. Anesth Analg. 1997; 84(1): 139-147.
26. Iida H, Ohata H, Iida M, Watanabe Y, Dohi S. Direct effects of alpha1- and alpha2-adrenergic agonists on spinal and cerebral pial vessels in dogs. Anesthesiology. 1999; 91(2): 479-485.
27. Ogawa Y, Iwasaki K, Aoki K, Kojima W, Kato J, Ogawa S. Dexmedetomidine weakens dynamic cerebral autoregulation as assessed by transfer function analysis and the thigh cuff method. Anesthesiology. 2008; 109(4): 642-650.
28. Kadoi Y, Saito S, Kawauchi C, Hinohara H, Kunimoto F. Comparative effects of propofol vs dexmedetomidine on cerebrovascular carbon dioxide reactivity in patients with septic shock. Br J Anaesth. 2008; 100(2): 224-229.
29. Iida H, Iida M, Ohata H, Michino T, Dohi S. Effects of dexmedetomidine on cerebral circulation and systemic hemodynamics after cardiopulmonary resuscitation in dogs. J Anesth. 2006; 20(3): 202-207.
30. Drummond JC, Dao AV, Roth DM, et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology. 2008; 108(2): 225-232.
31. Bekker A, Gold M, Ahmed R, et al. Dexmedetomidine does not increase the incidence of intracarotid shunting in patients undergoing awake carotid endarterectomy. Anesth Analg. 2006; 103(4): 955-958.
32. Fale A, Kirsch JR, McPherson RW. Alpha 2-adrenergic agonist effects on normocapnic and hypercapnic cerebral blood flow in the dog are anesthetic dependent. Anesth Analg. 1994; 79(5): 892-898.
33. Toda N. Alpha adrenergic receptor subtypes in human, monkey and dog cerebral arteries. J Pharmacol Exp Ther. 1983; 226(3): 861-868.
34. Segal IS, Vickery RG, Walton JK, Doze VA, Maze M. Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha 2 adrenergic receptor. Anesthesiology. 1988; 69(6): 818-823.
35. Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg. 1992; 75(6): 940-946.
36. Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Modulation of the acoustic startle response by the level of arousal: comparison of clonidine and modafinil in healthy volunteers. Neuropsychopharmacology. 2007; 32(11): 2405-2421.
37. Mahmoud M, Sadhasivam S, Sestokas AK, Samuels P, McAuliffe J. Loss of transcranial electric motor evoked potentials during pediatric spine surgery with dexmedetomidine. Anesthesiology. 2007; 106(2): 393-396.
38. Tobias JD, Goble TJ, Bates G, Anderson JT, Hoernschemeyer DG. Effects of dexmedetomidine on intraoperative motor and somatosensory evoked potential monitoring during spinal surgery in adolescents. Paediatr Anaesth. 2008; 18(11): 1082-1088.
39. Bloom M, Beric A, Bekker A. Dexmedetomidine infusion and somatosensory evoked potentials. J Neurosurg Anesthesiol. 2001; 13(4): 320-322.
40. Bala E, Sessler DI, Nair DR, McLain R, Dalton JE, Farag E. Motor and somatosensory evoked potentials are well maintained in patients given dexmedetomidine during spine surgery. Anesthesiology. 2008; 109(3): 417-425.
41. Oda Y, Toriyama S, Tanaka K, et al. The effect of dexmedetomidine on electrocorticography in patients with temporal lobe epilepsy under sevoflurane anesthesia. Anesth Analg. 2007; 105(5): 1272-1277.
42. Souter MJ, Rozet I, Ojemann JG, et al. Dexmedetomidine sedation during awake craniotomy for seizure resection: effects on electrocorticography. J Neurosurg Anesthesiol. 2007; 19(1): 38-44.
43. Ard J, Doyle W, Bekker A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesthesiol. 2003; 15(3): 263-266.
44. Fahy CJ, Okumura M. Sedation for paediatric stereotactic radiosurgery: the dexmedetomidine experience. Anaesth Intensive Care. 2004; 32(6): 809-811.
45. Ard JL Jr, Bekker AY, Doyle WK. Dexmedetomidine in awake craniotomy: a technical note. Surg Neurol. 2005; 63(2): 114-116.
46. Bekker AY, Kaufman B, Samir H, Doyle W. The use of dexmedetomidine infusion for awake craniotomy. Anesth Analg. 2001; 92(5): 1251-1253.
47. Mack PF, Perrine K, Kobylarz E, Schwartz TH, Lien CA. Dexmedetomidine and neurocognitive testing in awake craniotomy. J Neurosurg Anesthesiol. 2004; 16(1): 20-25.
48. Takenaka M, Iida H, Iida M, Dohi S. Intrathecal dexmedetomidine attenuates hypercapnic but not hypoxic cerebral vasodilation in anesthetized rabbits. Anesthesiology. 2000; 92(5): 1376-1384.
49. Kenney C, Simpson R, Hunter C, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007; 106(4): 621-625.
50. Vesper J, Haak S, Ostertag C, Nikkhah G. Subthalamic nucleus deep brain stimulation in elderly patients-analysis of outcome and complications. BMC Neurol. 2007; 7: 7.
51. Khatib R, Ebrahim Z, Rezai A, et al. Perioperative events during deep brain stimulation: the experience at Cleveland Clinic. J Neurosurg Anesthesiol. 2008; 20(1): 36-40.
52. Rozet I, Muangman S, Vavilala MS, et al. Clinical experience with dexmedetomidine for implantation of deep brain stimulators in Parkinson's disease. Anesth Analg. 2006; 103(5): 1224-1228.
53. Rauck RL, Eisenach JC, Jackson K, Young LD, Southern J. Epidural clonidine treatment for refractory reflex sympathetic dystrophy. Anesthesiology. 1993; 79(6): 1163-1169.
54. Tanskanen PE, Kytta JV, Randell TT, Aantaa RE. Dexmedetomidine as an anaesthetic adjuvant in patients undergoing intracranial tumour surgery: a double-blind, randomized and placebocontrolled study. Br J Anaesth. 2006; 97(5): 658-665.
55. Fieschi C, Agnoli A, Battistini N, Bozzao L, Prencipe M. Derangement of regional cerebral blood flow and of its regulatory mechanisms in acute cerebrovascular lesions. Neurology. 1968; 18(12): 1166-1179.
56. Uyar AS, Yagmurdur H, Fidan Y, Topkaya C, Basar H. Dexmedetomidine attenuates the hemodynamic and neuroendocrinal responses to skull-pin head-holder application during craniotomy. J Neurosurg Anesthesiol. 2008; 20(3): 174-179.
57. Ohata H, Iida H, Dohi S, Watanabe Y. Intravenous dexmedetomidine inhibits cerebrovascular dilation induced by isoflurane and sevoflurane in dogs. Anesth Analg. 1999; 89(2): 370-377.
58. Memis D, Turan A, Karamanlioglu B, Şeker Ş, Pamukçu Z. Dexmedetomidine reduces rocuronium dose requirement in sevoflurane anaesthesia. Curr Anaesth Crit Care. 2008; 19(3): 169-174.
59. Farag E, Chahlavi A, Argalious M, et al. Using dexmedetomidine to manage patients with cocaine and opioid withdrawal, who are undergoing cerebral angioplasty for cerebral vasospasm. Anesth Analg. 2006; 103(6): 1618-1620.
60. Farag E, Fiorella D, Robinson H, Anderson M, Ebrahim Z. Anesthetic management for wingspan stent insertion. Anesthesiology. 2008; 109(4): A485.
61. Smyth DD, Umemura S, Pettinger WA. Alpha 2-adrenoceptor antagonism of vasopressin-induced changes in sodium excretion. Am J Physiol. 1985; 248(6, pt 2): F767-F772.
62. Pettinger WA. Renal alpha 2-adrenergic receptors and hypertension. Hypertension. 1987; 9(1): 3-6.
63. Chen M, Lee J, Huang BS, Grekin RJ, Malvin RL. Clonidine and morphine increase atrial natriuretic peptide secretion in anesthetized rats. Proc Soc Exp Biol Med. 1989; 191(3): 299-303.
64. Billings FT 4th, Chen SW, Kim M, et al. alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol. 2008; 295(3): F741-F748.
65. Zornow MH, Scheller MS, Sheehan PB, Strnat MA, Matsumoto M. Intracranial pressure effects of dexmedetomidine in rabbits. Anesth Analg. 1992; 75(2): 232-237.
66. Hofer S, Steppan J, Wagner T, et al. Central sympatholytics prolong survival in experimental sepsis. Crit Care. 2009; 13(1): R11.
67. Kumagai M, Horiguchi T, Nishikawa T, Masaki Y, Tobe Y. Intravenous dexmedetomidine decreases lung permeability induced by intracranial hypertension in rats. Anesth Analg. 2008; 107(2): 643-647.
68. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2- adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology. 2003; 98(2): 428-436.
69. Maze M, Bonnet F. Receptor ligands-alpha 2-adrenergic receptor agonists. In: Evers AS, Maze M, eds. Anesthetic Pharmacology: Physiologic Principles and Clinical Practice. Philadelphia, PA: Churchill Livingstone, 2004: 473-489.
70. Coull JT, Jones ME, Egan TD, Frith CD, Maze M. Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage. 2004; 22(1): 315-322.
71. Venn RM, Bradshaw CJ, Spencer R, et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia. 1999; 54(12): 1136-1142.
72. Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth. 2002; 88(5): 669-675.
73. Grossman A, Weerasuriya K, Al-Damluji S, Turner P, Besser GM. Alpha 2-adrenoceptor agonists stimulate growth hormone secretion but have no acute effects on plasma cortisol under basal conditions. Horm Res. 1987; 25(2): 65-71.
74. Maze M, Virtanen R, Daunt D, Banks SJ, Stover EP, Feldman D. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesth Analg. 1991; 73(2): 204-208.
75. Wagner DS, Brummett CM. Dexmedetomidine: as safe as safe can be. Semin Anesth Perioperative Med Pain. 2006; 25(2): 77-83.
76. Joris J, Banache M, Bonnet F, Sessler DI, Lamy M. Clonidine and ketanserin both are effective treatment for postanesthetic shivering. Anesthesiology. 1993; 79(3): 532-539.
77. Multz AS. Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg. 2003; 96(4): 1054-1055.
78. Levanen J, Makela ML, Scheinin H. Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium. Anesthesiology. 1995; 82(5): 1117-1125.
79. Kim MH, Hahn TH. The effect of clonidine pretreatment on the perioperative proinflammatory cytokines, cortisol, and ACTH responses in patients undergoing total abdominal hysterectomy. Anesth Analg. 2000; 90(6): 1441-1444.
80. Spies CD, Dubisz N, Neumann T, et al. Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Crit Care Med. 1996; 24(3): 414-422.
81. Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007; 298(22): 2644-2653.
82. Ruokonen E, Parviainen I, Jakob SM, et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med. 2009; 35(2): 282-290.
83. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009; 301(5): 489-499.
84. Talke P, Tong C, Lee HW, Caldwell J, Eisenach JC, Richardson CA. Effect of dexmedetomidine on lumbar cerebrospinal fluid pressure in humans. Anesth Analg. 1997; 85(2): 358-364.
85. Aryan HE, Box KW, Ibrahim D, Desiraju U, Ames CP. Safety and efficacy of dexmedetomidine in neurosurgical patients. Brain Inj. 2006; 20(8): 791-798.
86. Goddeau RP Jr, Silverman SB, Sims JR. Dexmedetomidine for the treatment of paroxysmal autonomic instability with dystonia. Neurocrit Care. 2007; 7(2): 217-220.
87. Erkonen G, Lamb F, Tobias JD. High-dose dexmedetomidineinduced hypertension in a child with traumatic brain injury. Neurocrit Care. 2008; 9(3): 366-369.
88. Tobias JD. Bradycardia during dexmedetomidine and therapeutic hypothermia. J Intensive Care Med. 2008; 23(6): 403-408.
89. Spitzfaden AC, Jimenez DF, Tobias JD. Propofol for sedation and control of intracranial pressure in children. Pediatr Neurosurg. 1999; 31(4): 194-200.